FDA approves first gene therapy for paediatric spinal muscular atrophy

The FDA has given approval to AveXis for the first treatment of paediatric spinal muscular atrophy (SMA).

The post FDA approves first gene therapy for paediatric spinal muscular atrophy appeared first on European Pharmaceutical Review.

Original Article: FDA approves first gene therapy for paediatric spinal muscular atrophy

More From BioPortfolio on "FDA approves first gene therapy for paediatric spinal muscular atrophy"